Edition:
United States

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

31.50USD
11:29am EST
Change (% chg)

$-0.92 (-2.84%)
Prev Close
$32.42
Open
$32.00
Day's High
$32.00
Day's Low
$31.50
Volume
695
Avg. Vol
1,013
52-wk High
$48.42
52-wk Low
$16.65

Latest Key Developments (Source: Significant Developments)

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Beyondspring Inc ::BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN).BEYONDSPRING INC - INTERIM ANTI-CANCER EFFICACY DATA FROM PHASE 3 NSCLC CLINICAL TRIAL IS EXPECTED IN MID-2018.  Full Article

Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China
Thursday, 30 Nov 2017 09:58am EST 

Nov 30 (Reuters) - Beyondspring Inc ::BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY.BEYONDSPRING INC - ‍EXPECT CFDA FILINGS OF FIRST NDAS FOR BOTH CIN AND NSCLC INDICATIONS POTENTIALLY IN 2018​.  Full Article

BeyondSpring qtrly loss per share $‍0.68
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - BeyondSpring Inc :BeyondSpring reports third quarter 2017 operational and financial results.BeyondSpring Inc - qtrly loss per share $‍0.68​.  Full Article

BeyondSpring announces first patient enrolled in China
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - BeyondSpring Inc ::BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia.BeyondSpring-‍look forward to top line results, later in 2017, comparing plinabulin with pegfilgrastim from phase 2 portion of the phase 2/3 trial.  Full Article

China FDA approves ctas for Beyondspring's second global plinabulin registrational trial
Thursday, 6 Jul 2017 08:00am EDT 

July 6 (Reuters) - Beyondspring Inc ::China FDA approves ctas for beyondspring’s second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention.Beyondspring- approved company's clinical trial applications (ctas) to allow initiation of two global phase 2/3 trials for its lead asset, plinabulin.Beyondspring-Targeting reporting phase 2 efficacy data in 2h 2017, phase 3 interim data in 2018, submitting NDA in 2019 to FDA and CFDA for plinabulin.  Full Article

BeyondSpring prices initial public offering and concurrent private placement of $54.31 mln
Thursday, 9 Mar 2017 07:00am EST 

BeyondSpring Inc - : Prices initial public offering and concurrent private placement of $54.31 mln .Pricing of its initial public offering of 174,286 ordinary shares at a public offering price of $20.00 per share.  Full Article

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)